SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 518,600 shares, a growth of 287.6% from the April 15th total of 133,800 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio […]
SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants.
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) – Stock analysts at Chardan Capital lifted their FY2023 earnings per share estimates for shares of SAB Biotherapeutics in a research note issued on Tuesday, April 18th. Chardan Capital analyst K. Nakae now forecasts that the company will earn ($0.52) per share for the year, up from their […]
Silver Oak Securities Incorporated bought a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 51,941 shares of the company’s stock, valued at approximately $31,000. Silver Oak Securities Incorporated owned 0.12% of […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 138,200 shares, a decline of 30.1% from the March 15th total of 197,800 shares. Currently, 0.4% of the company’s shares are short sold. Based […]